Current Topics in the Management of Non–Muscle-Invasive Bladder Cancer

Presenter: Philippe E. Spiess
Restricted access

The current NCCN Guidelines for Bladder Cancer reflect the most up-to-date, evidence-based data relating to the evaluation and management of non–muscle-invasive bladder cancer (NMIBC). The most notable revision to the guidelines this year is the addition of pembrolizumab for a high-risk subset of patients not responding to bacillus Calmette-Guérin (BCG). It is anticipated that current BCG shortages will offer unique opportunities to promote and enhance clinical trials for patients with bladder cancer. Recent efforts to more precisely define BCG-unresponsive disease (adopted by the FDA) have been critical to standardizing definitions and evaluating the efficacy of clinical trials in bladder cancer.

Disclosures: Dr. Spiess has disclosed that he has no relevant financial relationships.

Correspondence: Philippe E. Spiess, MD, MS, FRCS(C), Department of Genitourinary Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Office 12538, Tampa, FL 33612. Email: philippe.spiess@moffitt.org
  • 1.

    American Cancer Society. Key Statistics for Bladder Cancer. Revised January 8, 2020. Accessed June 11, 2020. Available at: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html

    • Search Google Scholar
    • Export Citation
  • 2.

    Flaig TW, Spiess PE, Agarwal N, NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. Version 3.2020. Accessed January 17, 2020. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 3.

    Chang SS, Boorjian SA, Chou R, Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196:10211029.

  • 4.

    Babjuk M, Burger M, Compérat EM, European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 2019;76:639657.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Khanna A, Yerram N, Zhu H, Utilization of bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an era of bacillus Calmette-Guerin supply shortages. Urology 2019;124:120126.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Bandari J, Maganty A, MacLeod LC, Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Guérin. Eur Urol Focus 2018;4:481484.

  • 7.

    Kamat AM, Sylvester RJ, Böhle A, Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:19351944.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 35 35 35
PDF Downloads 7 7 7
EPUB Downloads 0 0 0